Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. - Wikidata - awgldk - TriplyDB

Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.

Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.

http://www.wikidata.org/entity/Q43741617

about

Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology The role of late I Na in development of cardiac arrhythmias Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment CaMKII-dependent regulation of cardiac Na(+) homeostasis Targets for therapy in sarcomeric cardiomyopathies Late Na(+) current and protracted electrical recovery are critical determinants of the aging myopathy Cardiac disease and arrhythmogenesis: Mechanistic insights from mouse models Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes Post-translational modifications of the cardiac Na channel: contribution of CaMKII-dependent phosphorylation to acquired arrhythmias Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo.Impact of detubulation on force and kinetics of cardiac muscle contraction.Inhibition of late sodium current suppresses calcium-related ventricular arrhythmias by reducing the phosphorylation of CaMK-II and sodium channel expressions Ca(2+) homeostasis in sealed t-tubules of mouse ventricular myocytes.Hypertrophic cardiomyopathy: a heart in need of an energy bar?Sodium MRI in human heart: a review.Novel aspects of excitation-contraction coupling in heart failure.Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations.A Spatially Detailed Model of Isometric Contraction Based on Competitive Binding of Troponin I Explains Cooperative Interactions between Tropomyosin and Crossbridges.Novel insights on the relationship between T-tubular defects and contractile dysfunction in a mouse model of hypertrophic cardiomyopathy.Effect of late sodium current inhibition on MRI measured diastolic dysfunction in aortic stenosis: a pilot study.Changes in Intracellular Na+ following Enhancement of Late Na+ Current in Virtual Human Ventricular Myocytes.Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm.Myocyte repolarization modulates myocardial function in aging dogs Post-partum variation in the expression of paternal care is unrelated to urinary steroid metabolites in marmoset fathers DIFFERENCES IN IONIC CURRENTS BETWEEN CANINE MYOCARDIAL AND PURKINJE CELLS.The arrhythmogenic consequences of increasing late INa in the cardiomyocyte.Electrophysiologic characteristics and pharmacologic response of human cardiomyocytes isolated from a patient with hypertrophic cardiomyopathy.Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.Selective inhibition of late sodium current suppresses ventricular tachycardia and fibrillation in intact rat hearts.Hypertrophic cardiomyopathy: The need for randomized trials Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation?Resveratrol protects rabbit ventricular myocytes against oxidative stress-induced arrhythmogenic activity and Ca2+ overload.Myocardial energetics in heart failure.The transverse-axial tubular system of cardiomyocytes.Decade in review--cardiomyopathies: Cardiomyopathy on the move.Passive ventricular remodeling in cardiac disease: focus on heterogeneity.Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations.A focus on the prognosis and management of ischemic heart disease in patients without evidence of obstructive coronary artery disease.

P2860

Q26765793-4CE42CFC-CB2E-4339-A169-D523E013F88B Q26823149-A059FBE7-6BF3-4420-8D00-C8FB71D53440 Q26863221-EB1CDF86-BD94-4249-90C9-2457F505D059 Q26997372-31FD58B8-AF6E-41AB-B371-1A9EE7CDA681 Q27027023-5BC1839D-3CDA-41D0-92B0-26F2EF6094DF Q27318671-5D240A89-315A-45B2-A92F-A4845BE09F8C Q28066019-5C4B1F4B-4FB9-430D-98AA-E5929F46CFFA Q28242903-B48F47DE-9FB1-4BCB-B464-B0B02783D497 Q28247689-A53B4E4F-1FB9-415C-9EBF-3A7BDA45271F Q28255887-7D934C4F-4932-4E03-9A7B-5BF215547B50 Q28292930-4BA5C29D-3109-4265-A142-380001B50669 Q30973910-B9E9C601-53CC-4F43-A80A-45CC12BFC3C1 Q33672949-312A24ED-EDF4-4477-88C1-D407D2082FB1 Q33681289-5FEDF28E-D306-4056-86AD-9E2F982A8F97 Q33998618-4304068A-34B5-468D-999B-7B6472A5ECCD Q34063733-2E6C1B77-B5B5-42AC-A4BD-8C04EB03C09F Q34462810-EF83CFB1-7D1A-48F6-9DE4-D84C3AA8F02E Q34652710-05408F37-3760-4456-BF53-455210BF05A6 Q34732430-EC11FDDB-6B27-488A-ACA1-346AE8976A24 Q35742414-C2F6C9D1-C9DA-484E-A503-84AFD682F31C Q35880670-5CC852AA-9BF4-4716-8CC2-759B7F5C265F Q35915087-06BA1525-E2DC-4CD9-BF28-E00CE341FE59 Q36201210-8AF7A1EF-2AAB-4061-AB63-E286B4673C50 Q36766366-BF8F241F-BAA1-4A51-9B6A-F9AC3D0E11AD Q36902443-ACD51708-A13A-4092-8C7E-835E44015214 Q37101362-C3CB4B7B-DE3E-40C3-8146-E4B0F0AC7096 Q37187840-97372B49-1204-4BC8-B7DE-D3CD55DE924E Q37345048-2154F3DA-647F-477E-A240-3F291F82374B Q37374476-66A6A7FD-59FE-4D53-A2BF-635C2C1F38A4 Q37495337-59C8074C-4D10-4262-A472-290EBB643949 Q37658443-E8CBF1CF-D773-4BC6-BCEC-465AE16E20B3 Q37659240-0DC6C9F4-1C72-4FD8-B119-80EF0B48EFDE Q37696227-BD7B69C6-B323-4528-A1EA-2FC571459A58 Q37729590-1FE9A71F-E205-478B-A7E9-623E75BE3777 Q38112349-1AA01EF4-3240-4CDF-B421-85D253E365C0 Q38121017-DC17F890-992E-4912-B021-1B6E7D5D99B7 Q38255416-B25AAD05-038C-4CFB-9EFD-754C004E4DEB Q38310158-CA8AA37F-87A7-41A4-86A2-D6CCB8BD0E2A Q38336102-26E7EF1E-3EF6-4C26-AE1D-433B644B3004 Q38574181-7985DD70-1914-4794-AE94-FF77361C1848

P2860

Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.

http://www.wikidata.org/entity/Q43741617

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Late sodium current inhibition ...... n hypertrophic cardiomyopathy.

@en

Late sodium current inhibition ...... n hypertrophic cardiomyopathy.

@nl

type

label

Late sodium current inhibition ...... n hypertrophic cardiomyopathy.

@en

Late sodium current inhibition ...... n hypertrophic cardiomyopathy.

@nl

prefLabel

Late sodium current inhibition ...... n hypertrophic cardiomyopathy.

@en

Late sodium current inhibition ...... n hypertrophic cardiomyopathy.

@nl

P1433

Q43741617-67D37BD6-2775-4230-BC7D-AC227A571BAE

P1476

Q43741617-37E0D7C1-9694-488F-8612-6598C07DBB9B

P2093

Q43741617-0136A635-1D9C-4C6A-B845-84CC4491108A

Q43741617-03F0F245-7828-49C3-B9DC-75C635C3C7CC

Q43741617-242F7888-28E3-45B8-BC3B-A71F5FCBF2AA

Q43741617-291A2993-539E-4266-83B1-1156797E43C5

Q43741617-4BDC330A-2243-4A00-899E-04119A875EE7

Q43741617-B36C6E5A-B4E0-41CF-8895-109660819F9E

Q43741617-BE1D489D-803B-46D0-80C0-F3BB02AD8F95

Q43741617-D048B0E6-E4C8-46CD-B73D-ED86338A530D

Q43741617-D2622708-1217-4A3D-A136-5DDD6807D32E

Q43741617-D6228B4F-3482-4549-BEB7-54746069040F

P304

Q43741617-984CED2A-A4D2-4B94-B938-7C73A5EFB24A

P31

Q43741617-9CA06565-A621-44F7-81C4-DA9DB482EA6B

P356

Q43741617-D8B95FCF-CA6D-4F0B-8052-39E53A6C8102

P407

Q43741617-EB0B541D-5A74-435E-807C-9B38AE2498D6

P433

Q43741617-4CEDC9FA-B4FF-482F-9335-98BE9A98D8D7

P478

Q43741617-14F560A4-1EC0-432B-AD26-D7DFA874C6A9

P50

Q43741617-B5D51F9F-25B7-4D2E-A2B4-AD5A8DD6FF43

Q43741617-C0AEDA78-0388-4A0A-A269-8DCCE289E3E8

Q43741617-D57122CF-3E79-4AAA-B8EF-1E316FBBB635

P577

Q43741617-F4485792-9130-4532-9215-8A62343E3695

P698

Q43741617-F95BB48D-C998-4D6C-998F-520032A697B3

P356

CIRCULATIONAHA.112.134932

P1433

P1476

Late sodium current inhibition ...... n hypertrophic cardiomyopathy.

@en

P2093

Alessandro Mugelli

http://www.w3.org/2001/XMLSchema#string

Benedetta Tosi

http://www.w3.org/2001/XMLSchema#string

Cecilia Ferrantini

http://www.w3.org/2001/XMLSchema#string

Chiara Tesi

http://www.w3.org/2001/XMLSchema#string

Corrado Poggesi

http://www.w3.org/2001/XMLSchema#string

Iacopo Olivotto

http://www.w3.org/2001/XMLSchema#string

Lina Yao

http://www.w3.org/2001/XMLSchema#string

Luiz Belardinelli

http://www.w3.org/2001/XMLSchema#string

Magdi Yacoub

http://www.w3.org/2001/XMLSchema#string

Martina Del Lungo

http://www.w3.org/2001/XMLSchema#string

P304

575-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.112.134932

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Elisabetta Cerbai

Francesca Stillitano

P577

2012-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23271797

http://www.w3.org/2001/XMLSchema#string